CDMO boosts capabilities at Cambridge location
Abzena, a contract development and manufacturing organization (CDMO) that provides integrated discovery, development, and manufacturing of biologics and antibody drug conjugates (ADCs), has upgraded to its research and development capabilities in Cambridge, UK. This features an investment in B cell discovery technologies.
As part of its investment in primary B cell antibody discovery technologies, the CDMO has implemented the Berkley Lights’ Beacon system, its branded platform that supports rapid antibody discovery, by isolating single B cells from a target-primed cohort of lymphocytes. According to the company, the technology enhances the capabilities of its R&D team in antibody discovery, enabling delivery of recombinant antibodies, in a shorter time span.
“The introduction of B cell discovery to Abzena’s capabilities is a significant new advancement to our antibody offering and is part of a number of new developments in the pipeline for Abzena,” says Campbell Bunce, the company’s chief scientific officer.
Protecting Temperature-Sensitive Pharmaceuticals, Without Unnecessary Plastic Waste
March 24th 2025Advances in the life sciences are driving a significant increase in the number of temperature-sensitive pharmaceuticals. The packaging industry is meeting the moment with advances of its own, including high-performance, environmentally-friendly materials that allow life science companies meet stringent thermal requirements and ambitious CO2e reduction goals. In this episode, TemperPack’s CEO Peter Wells shares insights from working with life sciences to move to certified biobased, home compostable, and curbside recyclable shipping solutions.